Lifesci Capital Comments on Kodiak Sciences Q3 Earnings

Kodiak Sciences Inc. (NASDAQ:KOD) – Analysts at Lifesci Capital issued their Q3 2025 EPS estimates for shares of Kodiak Sciences in a research report issued on Thursday, October 23rd. Lifesci Capital analyst P. Dolezal forecasts that the company will post earnings per share of ($1.09) for the quarter. Lifesci Capital has a “Outperform” rating and a $40.00 price target on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.45) per share. Lifesci Capital also issued estimates for Kodiak Sciences’ Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($3.47) EPS, FY2026 earnings at ($3.09) EPS, FY2027 earnings at ($2.97) EPS, FY2028 earnings at ($2.68) EPS and FY2029 earnings at ($1.61) EPS.

Several other brokerages have also recently issued reports on KOD. Jefferies Financial Group assumed coverage on shares of Kodiak Sciences in a report on Monday, September 22nd. They set a “buy” rating and a $15.00 target price on the stock. Wall Street Zen cut shares of Kodiak Sciences from a “hold” rating to a “sell” rating in a report on Saturday, October 11th. Chardan Capital reiterated a “neutral” rating and set a $14.00 target price on shares of Kodiak Sciences in a report on Monday, October 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Kodiak Sciences in a report on Wednesday, October 8th. Finally, Barclays upgraded shares of Kodiak Sciences from an “underweight” rating to an “equal weight” rating and raised their price target for the company from $7.00 to $17.00 in a report on Thursday, September 25th. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $19.17.

Kodiak Sciences Price Performance

Shares of Kodiak Sciences stock opened at $19.25 on Monday. Kodiak Sciences has a 1 year low of $1.92 and a 1 year high of $20.13. The firm’s 50-day moving average is $12.69 and its two-hundred day moving average is $7.59. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -5.07 and a beta of 2.67.

Kodiak Sciences (NASDAQ:KOD) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.02).

Institutional Trading of Kodiak Sciences

Institutional investors have recently bought and sold shares of the stock. Headlands Technologies LLC boosted its stake in Kodiak Sciences by 256.4% in the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock worth $30,000 after purchasing an additional 5,815 shares in the last quarter. US Bancorp DE raised its position in Kodiak Sciences by 131.7% during the 1st quarter. US Bancorp DE now owns 9,282 shares of the company’s stock worth $26,000 after buying an additional 5,276 shares during the last quarter. Vontobel Holding Ltd. purchased a new position in Kodiak Sciences during the 1st quarter worth approximately $28,000. SG Americas Securities LLC purchased a new position in Kodiak Sciences during the 3rd quarter worth approximately $228,000. Finally, Vanguard Personalized Indexing Management LLC raised its position in Kodiak Sciences by 21.7% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 15,070 shares of the company’s stock worth $56,000 after buying an additional 2,691 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.